Report

Medicines in Development for Neurological Disorders

Medicines in Development for Neurological Disorders

PhRMA July 31, 2013

America’s biopharmaceutical research companies are currently developing 420 medicines for patients suffering from neurological disorders, including epilepsy, Alzheimer’s disease, multiple sclerosis (MS) and Parkinson’s disease. As highlighted in a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Epilepsy Foundation, scientists around the globe are collaborating to find new or more effective treatments for patients with these complex disorders that attack the nervous system.

“Researchers have made tremendous advances in understanding how the nervous system works at the molecular and genetic levels which in turn has translated into the development of more effective treatments for neurological disorders,” said John J. Castellani, president and chief executive officer, PhRMA. “These developments mean new options and new hope for the millions of patients suffering from these devastating disorders. As an industry, we remain steadfast in our efforts to unlock the mysteries of these diseases and reduce their burden for generations to come.”

Neurological disorders consist of more than 600 conditions, impacting an estimated 50 million Americans every year. Although some are well known, many are rare disorders that affect a small number of patients who currently have access to few – if any – effective treatments.

The new report, “Medicines in Development for Neurological Disorders,” demonstrates how the newest advancements seek to treat the underlying mechanisms of neurological disorders.

Related Content: